Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
 - EconoTimes)
NEW YORK, April 10, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioAmber Inc. (NYSE:BIOA) who purchased shares pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/bioamber-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
